ClinicalTrials.gg
RecruitingNCT02828592Updated Oct 14, 2026

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

A Phase 2 interventional study of Fludarabine and Cyclophosphamide in Severe Aplastic Anemia, sponsored by Northside Hospital, Inc.. Recruiting at 2 sites in United States. Open to participants aged 1 Year to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Northside Hospital, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2016; still recruiting 10 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Year to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing cyclophosphamide in Anemia, Aplastic — 6 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Anemia, Aplastic.

Planned enrollment
32nd of 42
20 · median 31
Started
2016
with 2 others
Phase 2
26 of 44
5 open now
Registered
32nd of 44
by date

Among the 44 studies testing cyclophosphamide in Anemia, Aplastic, this one is the 32nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2016, is one of 26 in phase 2, and was the 32nd registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 44 studies testing cyclophosphamide in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 1 Year to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing cyclophosphamide in Anemia, Aplastic, or all of them as a file.
02

Study summary

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.

Read the detailed description

Mismatched haploidentical donors will be identified for patients with severe aplastic anemia. These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will be administered on Days 3 \& 4. Immunosuppression with Tacrolimus and MMF will begin on Day +5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180. Investigators hypothesize that haploidentical transplantation with the above-mentioned preparative regimen will have a \<30% graft failure rate. The one-sided exact Binomial test at 5% significance level will be used to test this hypothesis. The size of 20 patients provides the power of 92.5% for confirming the 30-day graft failure rate \<30%.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

Keywords

  • SAA
04

Who can participate

Ages eligible
1 Year to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction
  • Age \<= 65 years for previously treated and \<= 75 years for previously treated patients
  • >= 70%
  • Aplastic Anemia that meets the following criteria:

Peripheral Blood (must fulfill 2 of 3):

  • \<500 PMN/mm3
  • \<20,000
  • absolute reticulocyte count \<40,000/microL

Bone Marrow (must be either):

  • markedly hypocellular (\<25% of normal cellularity)
  • moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above

Exclusion criteria

Exclusion Criteria:

  • poor cardiac function ( \<40%)
  • poor pulmonary function ( \& FVC \<50% predicted)
  • poor liver function (bili >= 2mg/dL)
  • poor renal function (creatinine >= 2.0mg/dL or \<40mL/min)
  • prior transplant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Flu/Cy/TBI

    Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 \& 4.

    Drug: Fludarabine · Drug: Cyclophosphamide · Radiation: Total Body Irradiation · Drug: Rabbit ATG

Interventions

06

What researchers measure

Primary outcomes

  1. Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant

    Hypothesis is that following preparative regimen and bone marrow transplantation, the 30-day graft failure rate will be \<30%.

    Time frame: 2 years

Secondary outcomes

  1. Determine the incidence of regimen-related mortality at 100 days post transplantation by recording treatment-related adverse events

    Time frame: 2 years

  2. Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease at 100 days post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course

    Time frame: 2 years

  3. Determine incidence of chronic GVHD at 6 months and 1 year post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course

    Time frame: 2 years

  4. Estimate overall survival at 100 days and 1 year post transplantation by collecting survival information at those time points

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
  • Blood and Marrow Transplant Group of Georgia
    Atlanta, Georgia 30342, United States
    Recruiting
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • Melhem Solh, MD · Contactmsolh@bmtga.com · 404-255-1930
    • Stacey Brown · Contactstacey.brown@northside.com · 404-851-8238
    • Scott Solomon, MD · Sub investigator
    • H. Kent Holland, MD · Sub investigator
    • Asad Bashey, MD, PhD · Sub investigator
    • Lawrence Morris, MD · Sub investigator
    • Melhem Solh, MD · Principal investigator
08

References and documents

Publications

  • Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, Smith BD, Matsui WH, Goodman SN, Ambinder RF, Jones RJ. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-41. doi: 10.1182/blood-2009-06-225375. Epub 2009 Dec 16. PubMed 20018919 ↗
  • Socie G. Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematology Am Soc Hematol Educ Program. 2013;2013:82-6. doi: 10.1182/asheducation-2013.1.82. PubMed 24319167 ↗
  • Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;2013(1):76-81. doi: 10.1182/asheducation-2013.1.76. PubMed 24319166 ↗
  • Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19. PubMed 22517900 ↗
  • Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33. doi: 10.1016/j.bbmt.2015.09.002. Epub 2015 Sep 7. PubMed 26359881 ↗
  • Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19. PubMed 25797174 ↗
  • Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19. PubMed 24842530 ↗
  • Rozman C, Marin P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet. 1987 Oct 24;2(8565):955-7. doi: 10.1016/s0140-6736(87)91432-2. PubMed 2889870 ↗
  • Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant. 2012 Dec;18(12):1876-82. doi: 10.1016/j.bbmt.2012.07.004. Epub 2012 Jul 11. PubMed 22796534 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2016 (actual). Primary completion is estimated for Aug 2027, 131 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 131 months is above that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2016
First posted
Jul 11, 2016
StartActual
Sep 9, 2016
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02828592
Lead sponsor
Northside Hospital, Inc.
Responsible party
Sponsor
First posted
Jul 11, 2016
Start date
Sep 9, 2016
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Melhem Solh, MD
Contact
msolh@bmtga.com
404-255-1930
Stacey Brown
Contact
stacey.brown@northside.com
404-851-8238
Melhem Solh, MD
principal investigator · Blood and Marrow Transplant Group of Georgia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion